DANAHER CORP /DE/
No SEC Form 4 filings for $DHR in the last 30 days.
See all $DHR insider activity →An earnings-season recap of Danaher and other research tools and consumables firms’ Q2 results. The group’s revenues beat consensus by 1.7% and next-quarter guidance matched expectations. Danaher reported $6.27B revenue, up 5.5% YoY, beating analysts by 2.7%, and its stock was up 1.6% to $204.36. Other cited names include AVTR, BRKR, SHC, and TMO.
Danaher (DHR) reported Q2 2026 results with $6.3B revenue (+5.5% YoY), adj. EPS $1.94 (+8%), and raised full-year 2026 adj. EPS guidance to $8.45–$8.60, but its bioprocessing unit missed expectations. The move pressured Sartorius and Bio-Rad (BIO), which has a $5B strategic stake in Sartorius. Bio-Rad reported Q2 net sales $651M flat YoY and launched a restructuring with $80–$90M pre-tax charges.
Thermo Fisher (TMO) and Danaher (DHR) both reported better-than-expected fiscal Q2 results. TMO said revenue rose 10% to $11.99B, GAAP diluted EPS to $4.68, and adjusted EPS to $6.03, and raised guidance. DHR showed improving core growth and high-single-digit adjusted EPS growth, with some revenue timing deferred. Hedge fund ownership rose for TMO but fell for DHR.
Over the past 7 days, alphai's AI scored 4 news stories mentioning DHR (DANAHER CORP /DE/). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent DHR coverage spans financial news, earnings and market movers.
The article provides a post-earnings snapshot for Danaher, highlighting a modest beat and small positive price reaction.
Guidance raise offsets a bioprocessing miss, but near-term sentiment risk remains tied to bioprocessing demand softness.
Uneven recovery and a trimmed outlook cap near-term confidence, increasing sensitivity to order-to-revenue conversion.
Leadership change plus guidance reaffirmation is a near-term sentiment catalyst, but no new financial numbers are provided.
Leadership transition is a governance and execution catalyst, but the article frames it mainly as reinforcing the Diagnostics growth narrative rather than changing near-term guidance.
alphai scores every news story that mentions DHR with an AI model for sentiment and relevance, and aggregates insider trades from DANAHER CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
An earnings-season recap of Danaher and other research tools and consumables firms’ Q2 results. The group’s revenues beat consensus by 1.7% and next-quarter guidance matched expectations. Danaher reported $6.27B revenue, up 5.5% YoY, beating analysts by 2.7%, and its stock was up 1.6% to $204.36. Other cited names include AVTR, BRKR, SHC, and TMO.
4 min readDanaher (DHR) reported Q2 2026 results with $6.3B revenue (+5.5% YoY), adj. EPS $1.94 (+8%), and raised full-year 2026 adj. EPS guidance to $8.45–$8.60, but its bioprocessing unit missed expectations. The move pressured Sartorius and Bio-Rad (BIO), which has a $5B strategic stake in Sartorius. Bio-Rad reported Q2 net sales $651M flat YoY and launched a restructuring with $80–$90M pre-tax charges.
4 min readThermo Fisher (TMO) and Danaher (DHR) both reported better-than-expected fiscal Q2 results. TMO said revenue rose 10% to $11.99B, GAAP diluted EPS to $4.68, and adjusted EPS to $6.03, and raised guidance. DHR showed improving core growth and high-single-digit adjusted EPS growth, with some revenue timing deferred. Hedge fund ownership rose for TMO but fell for DHR.
7 min readThe UN’s 2026 Sustainable Development Goals health report warns healthcare progress may stall as international funding declines. It says only 36% of 139 targets are on track or making moderate progress, while 49% move too slowly and 15% regressed. Separately, Danaher names Julie Sawyer Montgomery CEO in Oct 2026 and reaffirms 2026 guidance; Johnson & Johnson shifts leadership in Innovative Medicine; P&G expands Health Care after buying Thorne for $3.8bn; Heidi reports NHS AI adoption.
6 min readDanaher announced its board appointed Julie Sawyer Montgomery as President and CEO effective Oct. 1, 2026, replacing Rainer Blair, who stays as senior advisor until Mar. 31, 2027. The article links the move to her role growing Diagnostics revenue from about $6.0B to $11.0B since 2017 and highlights Danaher’s 2026 Q2 guidance cut and longer-term $31.7B revenue and $6.9B earnings targets for 2029.
5 min readAbbott Laboratories (ABT) reported fiscal Q2 2026 results, with sales up 13% reported and 4.8% comparable, GAAP diluted EPS $0.53 and adjusted $1.31, and raised full-year 2026 adjusted EPS guidance to $5.45-$5.60. Danaher (DHR) posted Q2 revenue $6.3B (+5.5% YoY) and adjusted EPS $1.94 vs $1.83 estimates, but cut full-year core revenue outlook upper end to 4% from 6%.
7 min readDanaher (DHR) reported Q2 results July 21, beating earnings estimates and raising adjusted EPS guidance. The company said Life Sciences trends improved, but bioprocessing revenue was weaker and it cut the upper end of full-year core revenue growth to 4% from 6%. Q2 revenue rose 5.5% to $6.3B; adjusted EPS guidance was lifted to $8.45-$8.60.
6 min readDanaher said its board selected Julie Sawyer Montgomery as President and CEO effective Oct 1, 2026. According to the company, she helped grow its Diagnostics platform revenue to about $11B from about $6B and tripled operating profit. Danaher also said Q3 and full-year 2026 guidance is unchanged and outgoing CEO Rainer Blair stays as senior advisor through Mar 31, 2027.
4 min readDanaher (NYSE:DHR) said its board appointed Julie Sawyer Montgomery as President and CEO effective Oct. 1, 2026, with Rainer Blair retiring that day and advising until Mar. 31, 2027. The company cited Diagnostics revenue rising from about $6.0B in 2017 to about $11.0B today and tripled operating profit, plus acquisitions of Masimo and pending StatLab. 2026 guidance unchanged.
2 min readDANAHER CORP /DE/ (DHR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d161342dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 FINAL VERSION AMENDED AND RESTATED DANAHER CORPORATION OMNIBUS INCENTIVE PLAN LONG-TERM GROWTH AWARD OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Amended and Restated Danaher Corporation Omnibu
3 min read
